Christopher S Hourigan
Overview
Explore the profile of Christopher S Hourigan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
129
Citations
3972
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Single Cell Spatial Transcriptomics Reveals Immunotherapy-Driven Bone Marrow Niche Remodeling in AML
Gui G, Bingham M, Herzog J, Wong-Rolle A, Dillon L, Goswami M, et al.
bioRxiv
. 2025 Feb;
PMID: 39975227
Given the successful graft-versus-leukemia cell treatment effect observed with allogeneic hematopoietic stem cell transplant for patients with refractory or relapsed acute myeloid leukemia, immunotherapies have also been investigated in the...
2.
Pyzer A, Dillon L, Sharon E, Karrison T, Zha Y, Fulton N, et al.
Blood Adv
. 2025 Feb;
PMID: 39928953
We conducted a multi-center, open-label, randomized phase II study to assess the efficacy of Nivolumab as maintenance therapy for patients with AML in first complete remission (CR) or CR with...
3.
Gui G, Ravindra N, Hegde P, Andrew G, Mukherjee D, Wong Z, et al.
Bone Marrow Transplant
. 2024 Nov;
60(2):154-160.
PMID: 39506075
Measurable residual disease (MRD) in adults with acute myeloid leukemia (AML) in complete remission is an important prognostic marker, but detection methodology requires optimization. Persistence of mutated NPM1 or FLT3-ITD...
4.
Gui G, Ravindra N, Hegde P, Andrew G, Mukherjee D, Wong Z, et al.
Bone Marrow Transplant
. 2024 Oct;
60(2):144-153.
PMID: 39455897
Routine genetic profiling of acute myeloid leukemia (AML) at initial diagnosis has allowed subgroup specific prognostication, drug development, and clinical management strategies. The optimal approach for treatment response assessment for...
5.
Hegde P, Andrew G, Gui G, Ravindra N, Mukherjee D, Wong Z, et al.
Bone Marrow Transplant
. 2024 Oct;
60(2):175-177.
PMID: 39424958
No abstract available.
6.
Komrokji R, Lanino L, Ball S, Bewersdorf J, Marchetti M, Maggioni G, et al.
Lancet Haematol
. 2024 Oct;
11(11):e862-e872.
PMID: 39393368
The WHO and International Consensus Classification 2022 classifications of myelodysplastic syndromes enhance diagnostic precision and refine decision-making processes in these diseases. However, some discrepancies still exist and potentially cause inconsistency...
7.
Aakash F, Gisriel S, Zeidan A, Bennett J, Bejar R, Bewersdorf J, et al.
Mod Pathol
. 2024 Sep;
37(12):100615.
PMID: 39322118
Myelodysplastic neoplasms/syndromes (MDS) are a heterogeneous group of biologically distinct entities characterized by variable degrees of ineffective hematopoiesis. Recently, 2 classification systems (the 5th edition of the World Health Organization...
8.
9.
McCarthy N, Gui G, Dumezy F, Roumier C, Andrew G, Green S, et al.
Leukemia
. 2024 Jun;
38(8):1667-1673.
PMID: 38890448
Measurable residual disease (MRD) surveillance in acute myeloid leukemia (AML) may identify patients destined for relapse and thus provide the option of pre-emptive therapy to improve their outcome. Whilst flow...
10.
Mukherjee D, Lawal R, Fitzhugh C, Hourigan C, Dillon L
Leukemia
. 2024 May;
38(7):1604-1608.
PMID: 38796530
No abstract available.